长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌的临床研究  

Clinical Study of Vinorelbine Plus Oxaliplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：卢进[1] 李晓[1] 陈萍[1] 尹序德[1] 白桦[1] 卫述群[1] 李维[1] 

机构地区：[1]四川省肿瘤医院,四川成都610041

出　　处：《四川肿瘤防治》2005年第3期148-150,共3页Sichuan Journal of Cancer Control

摘　　要：目的:观察长春瑞滨(NVB)联合奥沙利铂(LOHP)治疗晚期非小细胞肺癌的临床疗效及不良反应.方法:将经病理组织学或细胞学确诊为非小细胞肺癌的患者作为研究对象,60例患者随机分为治疗组和对照组,各30例.治疗组给予NVB加LOHP治疗,21天为一周期,用2周期;对照组给予NVB加DDP(顺铂)治疗,21天为一周期,用2周期.结果:总有效率治疗组为43.3%,对照组为40.0%(P>0.05).不良反应以白细胞减少、恶心、呕吐以及周围神经炎为主,Ⅲ～Ⅳ度的恶心、呕吐、肾功能损害及心功能不全主要发生在对照组,周围神经炎主要发生在治疗组(P<0.05).结论:长春瑞滨联合奥沙利铂治疗晚期非小细胞肺癌的近期疗效与长春瑞宾联合顺铂治疗的疗效相似,均有较好的疗效.但长春瑞滨联合奥沙利铂组的不良反应比长春瑞滨联合顺铂组轻,病人更容易耐受,可以作为晚期非小细胞肺癌的一线治疗方案,更适宜老年患者及心肺功能不全的患者.Objective： To evaluate the efficacy and toxicity of vinorelbine （NVB） combined with oxaliplatin （LOHP） in the treatment of advanced non - small cell lung cancer（NSCLC）. Methods： 60 patients with advanced NSCLC diagnosed by pathology or cytology were randomly divided into study group （ NVB ＋ LOHP） and control group （ NVB ＋ DDP）. Each group had 30 patients. All patients received two cycles, 21 days as a cycle. Results： The overall response rate was 43.3% in the study group and 40.0% in the control group （ P 〉 0. 05 ）. The main toxicities included leukopenia, nausea/vomiting and peripheral neuritis. Grade Ⅲ,Ⅳ nausea /vomiting, renal toxicity and cardiac insufficiency occured more frequently in the control group, peripheral neuritis occured more fiequently in the study group （ P 〈 0.05 ）. Conclusion： Both of the two regimens of vinorelbine plus oxaliplatin and vinorelbine plus cisplatin are effective in the treatment of advanced NSCLC, and the former may be safer than the latter, especially for older patients and the patients with cardiopulmonary insufficiency.

关 键 词：长春瑞滨 奥沙利铂 顺铂 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]